Large real-world study shows GLP-1 drugs deliver 16% average weight loss in digital care

Half a million people. That's the scale of the largest real-world study yet conducted on how GLP-1 obesity drugs actually work when prescribed through digital clinics, outside the controlled environment of a pharmaceutical trial. The findings, released by the Digital Clinical Excellence Network, suggest that these medications—which have dominated conversations about weight management for the past two years—deliver results that match or exceed what researchers saw in their lab settings.

The DiCE REALM study pooled anonymized patient data from nine regulated UK digital healthcare providers to examine what happened when adults accessed GLP-1 treatments online. After twelve months, the average weight loss across the cohort was just over 16 percent. That figure matters because it comes from real people taking real doses in real life, not from carefully selected trial participants in ideal conditions. Thirty-seven percent of those who stuck with treatment for the full year lost more than a fifth of their body weight. The proportion of patients classified as having Class III obesity—the most severe category—fell by 75 percent.

What makes this study particularly significant is not just the scale but what it reveals about access. The data showed that patients using these digital services came from across the entire spectrum of socioeconomic deprivation. This challenges a common assumption about obesity treatment in Britain: that expensive private medications remain the province of the wealthy. Instead, the evidence suggests that digitally enabled care—where patients consult doctors online and receive prescriptions by post—can democratize access while still expanding choice. People who might never walk into a private clinic are finding these treatments through their phones.

Until now, most evidence about GLP-1 effectiveness came from clinical trials, where researchers carefully control dosing, monitor adherence, and track outcomes in structured settings. Those studies showed the drugs work. But they don't tell you what happens when a nurse practitioner in Manchester prescribes semaglutide to a patient they've never met in person, or when someone in Bristol decides to stop their medication because of side effects, or when a patient in Leeds adjusts their own dose based on how they're feeling. The DiCE REALM study captures all of that messiness—and finds that the drugs still deliver substantial results.

Stuart Flint, the study's principal investigator and an associate professor of obesity psychology at the University of Leeds, framed the research as a bridge between two worlds. Clinical trials remain the gold standard for proving a drug works. But most eligible adults in the UK who want GLP-1 treatment are not enrolling in trials. They're going online, paying privately, and getting prescriptions from digital providers. "Because most eligible UK adults currently access these medicines privately through digital services," Flint said, "this research offers important insights that complement clinical trials and better reflect everyday practice." In other words, if you want to understand how obesity care actually happens in Britain in 2026, you need to look at what's happening on screens, not in research hospitals.

The study was conducted in collaboration with IQVIA, a major clinical research organization, lending it institutional weight. But the real weight here is the half-million patient records. That's not a sample. That's a population. And it's telling policymakers, clinicians, and the public something clear: digital delivery of GLP-1 treatments works at scale, reaches across class lines, and produces outcomes that justify the hype. What happens next—whether this evidence reshapes how the NHS thinks about obesity care, whether it influences regulation, whether it changes who gets access and how—remains to be written.